All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
FMS-like tyrosine kinase 3 (FLT3) is a commonly occurring gene mutation in approximately 30% of patients with acute myeloid leukemia (AML). Midostaurin is a multikinase, first-generation, type 2 inhibitor that directly inhibits FLT3 signaling and induces apoptosis in FLT3-mutated leukemic cells. The pivotal RATIFY trial, previously reported by the AML Hub, demonstrated that midostaurin significantly reduced mortality in adult patients aged <60 years with newly diagnosed FLT3-mutated AML.1
The AML Hub is pleased to present a visual abstract summarizing the efficacy and safety outcomes from a phase IIIb trial (NCT03379727) of midostaurin plus idarubicin or daunorubicin in young (≤60 years) and older (≥60 years) patients with newly diagnosed FLT3-mutated AML.1
Subscribe to get the best content related to AML delivered to your inbox